KNOXVILLE, Tenn., May 5 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals (BULLETIN BOARD: PVCT) , an innovative pharmaceutical company engaged in the research and development of breakthrough technologies for psoriasis, breast cancer and other serious diseases announced today that the CEO Craig Dees, Ph.D. will be presenting to a meeting of the Society of Financial Analysts Los Angeles Chapter from noon to 1:30 pm on Tuesday, May 10, 2005. The lunch meeting, which will be held at L.A.'s Omni Hotel Downtown, will provide members of the Los Angeles investment community the opportunity to hear the Provectus story and to ask questions of Dr. Dees relating to the Company's ongoing clinical work for its novel approach to treating cancer and serious skin conditions.
Dees will discuss the company's new cancer drug, Provecta, which will begin human clinical trials later this year. In addition to background information on the discovery and development of the drug, which has a major advantage over current therapies, Dees will discuss pre-clinical trial results and expected outcomes from upcoming clinical trials.
About Provectus Pharmaceuticals Inc.:
Provectus Pharmaceuticals Inc. is a pioneering pharmaceutical company actively engaged in the design, development and marketing of pharmaceutical technologies for the treatment of liver, breast and prostate cancer and metastatic melanoma. In addition, Provectus is developing treatments for skin diseases such as psoriasis. Provectus' patented approach targets abnormal or diseased cells in its design of treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis and eczema. Clinical studies are already in process for the Company's topical agent Xantryl. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl. Although still in the early stages of development, pre-clinical studies have shown that Provecta(TM), when injected directly into a tumor, not only kills the treated tumor but also may protect against its spreading throughout the body.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011. For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com/.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
Provectus Pharmaceuticals Inc.CONTACT: Matt Clawson (investors) of Allen & Caron Inc, +1-949-474-4300,matt@allencaron.com; Peter Culpepper of Provectus Pharmaceuticals Inc.,+1-865-769-4011, culpepper@pvct.com
Web site: http://www.pvct.com/